This is a very complicated area. We've been spending many months, if not years, thinking about an approach that could allow us to balance an appropriate protection of genetic information while protecting the premiums for the vast majority of Canadians.
It requires significant analysis and understanding of the implications before you would commit to that kind of approach. The reality is that we're approaching that time when we're prepared to be moving forward on that, after very careful consideration. This is not something we've pulled out in the last couple of weeks.
I will quickly respond. Everybody wants the appropriate use of genetic information. We understand very clearly as an industry that understanding genetic information will allow us to provide better treatments. It provides better outcomes for people. There are advantages to everyone from being able to access that information.
Cutting that off from us precludes not only the underwriting use of that information, but the diagnostic and treatment information as well. We think it's a very broad and problematic approach to this issue.